EA
ACHN

Emerald Advisers’s Achillion Pharmaceuticals ACHN Stock Holding History

Emerald Advisers’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-130,919
Closed -$395K – 373
2013
Q3 		$395K Sell
130,919
-644,069
-83% -$4.41M 0.02% 293
2013
Q2 		$6.34M Buy
+774,988
New +$5.92M 0.39% 89

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Emerald Advisers's ACHN Position: Q4 2013 in Review

Emerald Advisers sold out of Achillion Pharmaceuticals (ACHN) in Q4 2013, closing a stake of 130,919 shares — an estimated $395K sold.

Emerald Advisers first reported a position in ACHN in Q2 2013 and held it in 2 quarters. The position peaked at $6.34M in Q2 2013. 93 funds tracked by Wall St. Rank hold ACHN as of Q4 2013.

  • Emerald Advisers reported no remaining Achillion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Emerald Advisers sold 130,919 Achillion Pharmaceuticals shares in Q4 2013, an estimated $395K.
  • Emerald Advisers first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Emerald Advisers's Achillion Pharmaceuticals position peaked at $6.34M in Q2 2013.
  • 93 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2013.

Based on Emerald Advisers's 13F filing for Q4 2013, filed 30 Jan 2014.